OncLive® On Air

Highlights from the PER® CME activity "Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Mara Antonoff, MD, FACS; Laura Alder, MD; and Stephanie Worrell, MD, FA...

In today’s episode, we spoke with Anne Chiang, MD, PhD, to discuss the rapidly evolving treatment landscape in small cell lung cancer (SCLC) and what this new era of innovation means for patients. Dr Chiang is an associate professor of medicine in the Section of Medical Oncology at Yale School of Medicine and associate cancer center director for clinical initiatives at Yale Cancer Center in New Ha...

In today’s episode, we sat down with Megan Kruse, MD; and Sophia O’Brien, MD. Dr Kruse is a breast medical oncologist at Cleveland Clinic in Ohio. Dr O’Brien is an assistant professor of clinical radiology in the Divisions of Nuclear Medicine and Breast Imaging, as well as the associate program director of the Diagnostic Radiology Residency, at Penn Medicine in Philadelphia, Pennsylvania. In our e...

Highlights from the PER® CME activity "Cases and Conversations™: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Marwan Fakih, MD, Kristen Ciombor, MD, MSCI, and Van Karlyle Morris, MD, discuss the treatment of advanced s...

In today’s episode, we spoke with David Carbone, MD, PhD. Dr Carbone is a professor of internal medicine at The Ohio State University, co-leader of the Translational Therapeutics Program and director of the Thoracic Oncology Center at the Ohio State University Comprehensive Cancer Center–James, as well as the Barbara J. Bonner Chair in Lung Cancer Research in Columbus. In our exclusive interview,...

In today’s episode, we sat down with Sarah Sammons, MD. Dr Sammons is associate director of the Metastatic Breast Cancer Program and a senior physician at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, both in Boston, Massachusetts. In our exclusive interview, Dr Sammons discussed the rationale for and findings from a phase 2 study (NCT064492...

Welcome to OncLive On Air ®! I’m your host today, Courtney Flaherty. OncLive On Air is a podcast from OncLive ®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’...

In this podcast, experts John V. Heymach, MD, PhD, and Anne S. Tsao, MD, MBA, FASCO, FACHE, discuss PD-1/CTLA-4, EGFR/PD-1, and DLL3 targeting bispecific antibodies, with a focus on thoracic malignancies.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology , hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medi...

Welcome to OncLive On Air ®! I’m your host today, Courtney Flaherty. OncLive On Air is a podcast from OncLive ®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’...

In today’s episode, we welcomed Quinto Gesiotto, MD, a malignant hematologist at Tampa General Hospital in Florida. In the exclusive interview, Dr Gesiotto explored the evolving role of TKIs in the treatment of patients with chronic myeloid leukemia (CML), including dosing patterns for ponatinib (Iclusig) in those with CML and other TKI data to emerge in the CML space at the 2025 ASH Annual Meetin...

Cancer, Character, and Calling: The Oncologist’s Journey , hosted by Girindra Raval, MD, is a podcast highlighting how top oncologists have navigated the field over the course of their careers, the passion that drove them to enter the oncology space, and the ongoing work that will continue to transform cancer care. Each episode, Raval will sit down with a top oncologist to dive into their backgrou...

Two Onc Docs , hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematolog...

Welcome to OncLive On Air ®! I’m your host today, Courtney Flaherty. OncLive On Air is a podcast from OncLive ®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’...

In today’s episode, we spoke with Alexander I. Spira, MD, PhD, FACP, FASCO. Dr Spira is co-director of the Virginia Cancer Specialists (VCS) Research Institute in Fairfax, director of the VCS Thoracic and Phase I Program, chief scientific officer of NEXT Oncology, and a clinical assistant professor at Johns Hopkins University in Baltimore, Maryland. In our exclusive interview, Dr Spira discussed t...

In this podcast, experts Mark Agulnik, MD; Sandra D’Angelo, MD; Mrinal M. Gounder, MD; and Sujana Movva, MD; discuss the complexities of diagnosing epithelioid sarcoma (ES) in a timely manner and the importance of multidisciplinary care in treating this disease at all stages.

In today’s episode, we spoke with Nicholas Short, MD. Dr Short is an associate professor in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Short discussed evolving factors at play for the treatment of patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL)....

Christopher Lieu, MD, expands on current treatment strategies and factors informing third-line sequencing decisions in mCRC.

In this podcast, experts Aakash Desai, MBBS, MPH; Ibiayi Dagogo-Jack, MD; and Patrick Forde, MBBCh, PhD, discuss how to decode the diagnosis of malignant pleural mesothelioma and review data to optimize frontline and subsequent treatment of this rare malignancy.

In today’s episode, our discussion features Aditya Bardia, MD, MPH, FASCO. Dr Bardia is a professor in the Department of Medicine in the Division of Hematology/Oncology, the director of Translational Research Integration, and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California. In our exclusive interview, Dr Bardia disc...

In today’s OncClub episode, we spoke with Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE, about a pragmatic real-world question in advanced urothelial carcinoma: Can upfront dose reduction of enfortumab vedotin-ejfv (Padcev) improve tolerability, particularly neuropathy and treatment interruption, without compromising clinical outcomes in patients with bladder cancer? Dr Sedhom is co-...

In today’s episode, recorded in recognition of World Cancer Day, we spoke with Deb Schrag, MD, MPH. Dr Schrag is a medical oncologist at Memorial Sloan Kettering Cancer Center and a nationally recognized leader in cancer outcomes research, health equity, and evidence-based care delivery. In our exclusive interview, Dr Schrag discussed the importance of standardizing high-quality cancer care, addre...

In today’s episode, our discussion features Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS. Dr Whitman is medical director of the oncology service line with Atlantic Health System in Morristown, New Jersey. Dr Patel is an associate professor of dermatology and medicine at the GW School of Medicine & Health Sciences, as well as the director of the Cutaneous Oncology Program at the GW Cance...

In today’s episode, the discussion features Komal Jhaveri, MD, FACP, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, who reviewed the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in the management of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. She drew on findings from the phase 3 ASCENT-07 trial (NCT05840211), which evaluated s...

In today’s episode, Andrew Lipsky, MD, reviewed recent updates with BTK inhibitors in the chronic lymphocytic leukemia (CLL) treatment paradigm, including the clinical significance of the December 2025 FDA approval of pirtobrutinib (Jaypirca) in relapsed/refractory CLL and its effect on sequencing decisions for this disease. Dr Lipsky is an assistant professor of medicine at the Columbia Universit...